RxDoctor Payments Data

Melissa Steiner, PA

Medical · Indiana, PANPI 1588994370

Payments from drug & device makers

$6,691in general payments, 2019–2025

Across 386 payments — averaging $17.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$1K
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$1K
  • Boehringer Ingelheim$605
  • Amgen$539
  • AstraZeneca$439
  • E.r. Squibb & Sons, L.L.C.$420
  • plus $2K from 21 others
$3,650in research payments, 2019–2025

Across 9 payments — averaging $405.56 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$4K

What the payments were for

  • Food & beverage$6,686100%
  • Education$50%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,691 in reported general payments places this provider in the 90th percentile of 2,594 medical providers in Pennsylvania.

See all medical providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$11,703
Medicare patients
76
Services billed
153

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban188$193,212
EntrestoSacubitril/Valsartan38$38,670
XareltoRivaroxaban32$33,852
BrilintaTicagrelor25$19,330
Repatha SureclickEvolocumab16$12,229
Metoprolol Succinate128$2,349
Atorvastatin Calcium118$1,704
Metoprolol Tartrate213$1,628
SotalolSotalol Hcl38$1,446
Flecainide Acetate15$1,386
Labetalol Hcl50$1,329
Valsartan28$1,225
Diltiazem 24hr Er (Cd)Diltiazem Hcl31$1,084
ClopidogrelClopidogrel Bisulfate78$1,040
Lisinopril108$869

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$243$193,212188 claims
NovartisEntresto$419$38,67038 claims
Johnson & JohnsonXarelto$1,217$33,85232 claims
AstraZenecaBrilinta$439$19,33025 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,594 medical providers in Pennsylvania.

Other medical in Indiana

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →